Compare Recursion Pharmaceuticals Inc (RXRX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wipro Limited — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Wipro Limited trades at $1.7 (market cap $16.22B). The key difference: Wipro Limited is far larger — about 7.6× Recursion Pharmaceuticals Inc's market cap, and Wipro Limited pays a 5.19% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Wipro Limited for 41 Days on average.
| RXRX | WIT | |
|---|---|---|
Market Cap | $2.14B | $16.22B |
Volume | 30,789,535 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $6.79 | $3.06 |
52-Week Low | $2.84 | $1.61 |
Typical Hold Time | 23 Days | 41 Days |
Enterprise Value | $1.66B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
WIT trades at $1.70, up 1.8% today, but technical indicators are bearish with recent earnings misses. The company reported Q1 2027 revenue below expectations, though annual net income improved to $131.35B in 2025. Positive news includes AI-driven productivity gains and new cybersecurity partnerships, but analyst sentiment is mixed with a majority hold rating.
The outlook is cautious due to earnings volatility and competitive pressures, though valuation ratios like P/E of 12.78 appear reasonable. Key risks include client spending cuts and margin pressure from wage increases. Upside depends on execution of AI initiatives and large deal ramp-ups stabilizing financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
